Hologic stock leans on diagnostics and imaging

Hologic stock is tied to a diagnostics and breast-health business that sells screening, biopsy and surgical products across global markets. The company remains listed on Nasdaq and reports to the SEC as a U.S. issuer.

By Christina Vaughn, Background & Management desk. Reviewed on July 5, 2026 at 10:41 a.m. ET.

Hologic (US4364401012) is a Nasdaq-listed medical technology company built around women's health, diagnostics and breast-health systems. The company reports as a U.S. issuer and its core business spans screening, biopsy and surgical care tools used by hospitals and clinics.

Business mix

Hologic's portfolio is centered on recurring testing and installed-base equipment, which gives investors two operating levers: procedure volume and consumables demand. Its diagnostics franchise and breast-health products remain the most recognizable parts of the model.

U.S. market frame

The stock trades on Nasdaq, which keeps it within the U.S. healthcare and med-tech peer set that investors often compare on growth, margins and reimbursement sensitivity. That makes SEC reporting and quarterly execution more relevant than broad consumer-style demand swings.

Read more

More on Hologic stock and the company's filings can be found through the linked company page and investor materials.

Representative product

The ThinPrep cervical cancer screening system is one of Hologic's best-known products and illustrates the company's diagnostics-first positioning. It reflects a business built on laboratory testing, screening workflows and follow-on equipment rather than one-off device sales.

Stock context

Hologic shares trade on Nasdaq in U.S. dollars. As of July 5, 2026, no live quote was available in the provided source set, so the article focuses on the company's operating profile and listing context.

Fact box

• Company: Hologic, Inc.
• ISIN: US4364401012
• Ticker: HOLX
• Exchange: Nasdaq
• Sector / Industry: Health Care, Medical Devices
• Index membership: not verified in the provided source set
• Next earnings date: not yet officially scheduled

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.